For instance, melanoma and colon cancer patients harboring the same BRAF (V600E) mutation respond differently to BRAF inhibitors because colon cancer cells but not melanoma cells gain feedback activation of EGFR and its signaling pathway [11]. The gene discussed is BRAF; the disease is malignant colon neoplasm.